T Cell Immunity Testing

Examining T Cell Immune Response for Critical Decisions

Innovations in Immunity

inSIGHT™ T Cell diagnostic delivers a deeper understanding of patients' response to viral antigens

Assess current immune response for viral target
Confirm if virus specific CD4 and CD8 T Cells are present
Evaluate treatment decisions

Learn more about Eurofins Viracor inSIGHT™ for examining T cell response:

CMV T Cell Immunity Test

It's your job to keep patients safe; our job is to help you do it.

The Advantages of inSIGHT™

With inSIGHT™, you're now armed with the data to help answer critical questions: Is the patient's body producing a T Cell response? Is that response strong enough to make treatment adjustments? Are they ready to discontinue antiviral medication?

For Clinical Staff

Reports CD4 and CD8 responses separately
Provides numerical values for various reportables
Ability for result consultation with scientific liaisons

For Lab Staff

Does not require additional staff or training
Live cell ambient shippers available
Simple blood draw, no extra processing to isolate PBMC

IDWeek 2021 - "Gain inSIGHT into an Immunocompromised Patient's T Cell Immune Response featuring: CMV and SARS-CoV-2"

Dr. Nirav Raval
Medical Director of Thoracic Transplant, Transplant Cardiologist
Advent Health

Dr. Fareed Khawaja
Assistant Professor, Department of Infectious diseases, Infection Control and Employee Health
University of Texas MD Anderson Cancer Center

Dr. Steve Kleiboeker
Vice President of Research and Development
Eurofins US Clinical Diagnostics

Join Dr.'s Raval, Khawaja and Kleiboeker to learn more about virus-specific T cell immunity for CMV and SARS-CoV-2. Dr. Raval, a board-certified Cardiologist, will share his experience utilizing the CMV T Cell Immunity panel in heart transplant patients. Dr. Khawaja, an Infectious Disease physician, will present his experience with CMV cellular immunity in hematopoietic cell transplant recipients with low level viremia. Finally, Dr. Kleiboeker will describe the new SARS-CoV-2 inSIGHT T Cell Immunity test as well as discuss future T Cell Immunity testing innovations to come.

Download IDWeek 2021 Presentation

The 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR - "Innovative Diagnostics to Help Manage HSCT Complications Post-Transplant"

Dr. Roy Chemaly
MD, MPH, FIDSA, FACP
University of Texas MD Anderson Cancer Center

Dr. Fareed Khawaja
MD
University of Texas MD Anderson Cancer Center

Dr. Steve Kleiboeker
Vice President of Research and Development
Eurofins US Clinical Diagnostics

Learn about an ongoing study which Dr. Chemaly and his team at MD Anderson have utilized CMV inSIGHT™ T Cell Immunity testing to:

Identify cellular therapy recipients (both on and off letermovir for prophylaxis) who are high risk for clinically significant CMV infection.
Assess the benefit of early treatment of low level CMV viremia who are not on letermovir prophylaxis and high risk for clinically significant CMV infection
Determine utility of the CMV inSIGHT™ T Cell Immunity test in the management of low level CMV viremia in high and low risk patient populations on letermovir.

Download Tandem Meetings 2022 Presentation

T Cell Immunity Testing - Flow Cytometry

How It Works

inSIGHT™ utilizes intracellular cytokine staining analyzed by flow cytometry to measure the strength of T cell responses to viral specific antigens or proteins. It evaluates and reports the activity of CD4 and CD8 T Cell responses separately.

Results Reporting

… Unlike ELISpot or QuantiFERONassays, ICS can thus provide both quantitative and qualitative characteristics of CMV-specific T cells.”

Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. Apr 15 2010;89(7):779-95.

Results For:

CMV inSIGHT™ T Cell Immunity

CMV Antigen • CD4 • CD8 • Control • Cell Viability

30360 - CMV inSIGHT™ T Cell Immunity Panel